Bioxytran, Inc.
BIXT
$0.02
$0.005.42%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 209.53% | 92.28% | -34.22% | -41.71% | -58.49% |
| Depreciation & Amortization | 68.18% | 50.00% | 45.57% | 30.68% | -3.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.17% | 66.37% | -16.90% | -37.00% | -53.37% |
| Operating Income | -134.17% | -66.37% | 16.90% | 37.00% | 53.37% |
| Income Before Tax | -41.87% | 10.17% | 10.79% | 12.19% | 28.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.87% | 10.17% | 10.79% | 12.19% | 28.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | -41.87% | 10.17% | 10.29% | 11.02% | 27.01% |
| EBIT | -134.17% | -66.37% | 16.90% | 37.00% | 53.37% |
| EBITDA | -134.17% | -66.57% | 17.00% | 37.12% | 53.43% |
| EPS Basic | -23.85% | 12.29% | -26.78% | -51.74% | -16.59% |
| Normalized Basic EPS | -16.67% | 15.12% | -10.00% | -57.39% | -23.29% |
| EPS Diluted | -23.85% | 12.29% | -26.78% | -51.74% | -16.59% |
| Normalized Diluted EPS | -16.67% | 15.12% | -10.00% | -57.39% | -23.29% |
| Average Basic Shares Outstanding | 4.83% | -19.41% | -34.35% | -41.43% | -36.38% |
| Average Diluted Shares Outstanding | 4.83% | -19.41% | -34.35% | -41.43% | -36.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |